Parnell Pharmaceuticals Holdings Ltd
PARNF · OTC
12/31/2016 | 9/30/2016 | 6/30/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -24.41 | -2.69 | 0.00 | -1.48 |
| Quality | ||||
| ROIC | -2.38% | -18.23% | 0.00% | -20.43% |
| Gross Margin | 64.05% | 40.90% | 0.00% | 37.96% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 2,806,682.49% | 2,630,370.74% | 2,696,398.75% | 2,496,130.16% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -24.41 | -2.69 | 0.00 | -1.48 |
| Interest Coverage | -0.43 | -9.74 | 0.00 | -22.46 |
| Efficiency | ||||
| Inventory Turnover | 0.73 | 0.73 | 0.00 | 0.73 |
| Cash Conversion Cycle | -15.96 | -81.44 | 0.00 | 140.43 |